The likelihood of receiving treatment for localized prostate cancer varies by race and insurance status or type, according to study data presented at the American Society of Clinical Oncology’s 2023 Genitourinary Cancers Symposium in San Francisco, California.

The study included 616,479 men diagnosed with localized prostate cancer from 2010 to 2017 identified using the National Cancer Database. Of these, 29%, 44%, and 28% had low-, intermediate-, and high-risk cancer, respectively.

Among men with high-risk disease, Black men had significant 37% lower odds of treatment compared with White men, Madison Novosel, MPH, of the Yale School of Public Health in New Haven, Connecticut, and colleagues reported. Among those with intermediate-risk disease, Black men had significant 22% lower odds of treatment. Across all risk strata, Asian men had significant 18% lower odds of treatment compared with White men. Among men with high-risk disease, American Native/Alaskan Native patients had significant 42% lower odds of treatment compared with White men.

Continue Reading

The investigators also linked insurance status to likelihood of treatment. Uninsured and Medicaid-insured patients had significant 59% and 31% lower odds of treatment, respectively, compared with patients with other types of insurance. Among Black patients, insurance status did not affect the likelihood of non-treatment.

“Patient race and insurance are significantly associated with non-treatment for aggressive prostate cancer,” the authors concluded in a study abstract.

Disclosure: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.


Novosel M, Smani S, Marks VA, et al. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Presented at: ASCO GU 2023, San Francisco, California, February 16-18. Abstract 307.